Mihara S, Hara S, Ueda M, Ide M, Fujimoto M
Shionogi Research Laboratories, Shionogi & Co., Ltd., Osaka, Japan.
Eur J Pharmacol. 1989 Nov 21;171(2-3):179-87. doi: 10.1016/0014-2999(89)90106-4.
We studied the actions of a potent thromboxane A2/prostaglandin in H2 (TP) receptor antagonist, (+/-)-(5Z)-7-[3-endo-[(phenylsulfonyl)amino]bicyclo [2.2.1]hept-2-exo-yl]heptenoic acid (S-145) on vascular and platelet receptors in the pig. S-145 showed almost the same affinity for both receptors in ligand binding studies with [3H]U46619 or [3H]SQ29, 548. The binding affinity of S-145 was 5-8 times higher than that of SQ29,548, a well-characterized TP receptor antagonist. However, S-145 inhibited U46619-induced contractions of pig coronary arteries with an IC50 value 52.5 times lower than that of SQ29,548, and was approximately equipotent with SQ29,548 in inhibiting U46619-induced secondary aggregation of pig platelets. Detailed kinetic studies on [3H]S-145 binding revealed that the apparent discrepancy between the pharmacological potency of S-145 in platelet and vascular systems was not due to tissue selectivity, but its small association constants for both receptors.
我们研究了一种强效血栓素A2/前列腺素H2(TP)受体拮抗剂,(±)-(5Z)-7-[3-内-[(苯磺酰基)氨基]双环[2.2.1]庚-2-外-基]庚烯酸(S-145)对猪血管和血小板受体的作用。在使用[3H]U46619或[3H]SQ29548进行的配体结合研究中,S-145对两种受体显示出几乎相同的亲和力。S-145的结合亲和力比已充分表征的TP受体拮抗剂SQ29548高5至8倍。然而,S-145抑制U46619诱导的猪冠状动脉收缩的IC50值比SQ29548低52.5倍,并且在抑制U46619诱导的猪血小板二次聚集方面与SQ29548大致相当。对[3H]S-145结合的详细动力学研究表明,S-145在血小板和血管系统中的药理效力之间的明显差异并非由于组织选择性,而是由于其与两种受体的小缔合常数。